Does Iowa Medicaid Cover GLP-1 Weight Loss Drugs in 2026?

Last updated: June 25, 2026 | Reading time: ~8 minutes | Reviewed by Dr. Marcus Tan, MD

Direct answer — Iowa Medicaid and GLP-1s in 2026

As of 2026, Iowa Medicaid covers GLP-1 medications for type 2 diabetes with prior authorization, but it does not cover any GLP-1 for weight loss or obesity alone. Wegovy and Zepbound actually appear on Iowa’s statewide Preferred Drug List as “Preferred” — but both carry a note that the weight-loss indication is not covered, so coverage is limited to their other FDA-approved uses (cardiovascular-risk reduction, obstructive sleep apnea, and MASH). There is no anti-obesity drug class on the Iowa PDL at all. In short: a GLP-1 may be covered if your prescription is tied to diabetes or another covered diagnosis, but never for weight loss by itself.

Important — verify your specific plan

Iowa uses a single statewide Preferred Drug List (PDL), and all three managed-care plans — Iowa Total Care, Wellpoint Iowa (formerly Amerigroup), and Molina Iowa — follow the same list and the same prior-authorization criteria. The PDL and PA rules can change, so always confirm your current coverage by calling your MCO’s member services line and asking about the specific drug and the exact diagnosis on your prescription.

Iowa Medicaid GLP-1 coverage at a glance

Drug	FDA-Approved Indication	Iowa Medicaid Coverage 2026	Prior Authorization?
Ozempic	Type 2 diabetes	Covered (Preferred)	Yes
Wegovy	Weight management; cardiovascular-risk reduction	Preferred, BUT weight-loss NOT covered; CV-risk indication only	Yes
Mounjaro	Type 2 diabetes	Covered (Preferred)	Yes
Zepbound	Weight management; obstructive sleep apnea	Weight-loss NOT covered; OSA indication only	Yes
Trulicity	Type 2 diabetes	Covered (Preferred)	Yes
Rybelsus	Type 2 diabetes	Covered (Preferred)	Yes

GLP-1s for type 2 diabetes on Iowa Medicaid

If you have type 2 diabetes, Iowa Medicaid covers GLP-1 receptor agonists with prior authorization. Because Iowa runs a single statewide PDL, the preferred diabetes agents are the same no matter which MCO you have. The preferred GLP-1s for diabetes are:

Mounjaro (tirzepatide)
Ozempic (semaglutide)
Trulicity (dulaglutide)
Victoza (liraglutide)
Rybelsus (oral semaglutide)
Exenatide

Non-preferred diabetes agents — such as Bydureon BCise and Soliqua — can still be covered, but only after additional steps (some older or generic versions of the preferred molecules also sit in the non-preferred tier). Note that Ozempic is preferred in Iowa, which corrects a common assumption that it is non-preferred.

The diabetes prior-authorization form (470-5259) asks the prescriber to document specific clinical details before approval. Key requirements include:

A confirmed type 2 diabetes diagnosis.
A current A1C value on file. Iowa does not publish a numeric A1c floor for approval, so do not assume a specific cutoff — what matters is that a current lab value is documented.
No DPP-4 inhibitor and GLP-1 in combination — that pairing will not be approved.
For a non-preferred agent, documented trials and failures of three preferred agents from three different drug classes (step therapy).

Critically, the form states that requests submitted for weight loss will be denied. The diabetes pathway is strictly for diabetes management.

Wegovy & Zepbound for weight loss on Iowa Medicaid

This is where Iowa surprises people. Both Wegovy and Zepbound appear on the Iowa PDL marked as “Preferred.” That sounds like good news — until you read the attached comment code, which states “PA Required. Weight loss indication not covered.” In other words, the drugs are on the list, but the weight-loss use is explicitly excluded. There is no anti-obesity drug class on the Iowa PDL at all — no Saxenda, Contrave, Qsymia, or phentermine.

So when can Wegovy or Zepbound actually be covered? Only for their non-weight-loss FDA indications, documented on the non-diabetes PA form (470-0058):

Wegovy for cardiovascular-risk reduction: BMI of 27 or higher plus established cardiovascular disease, age 18 or older.
Zepbound for obstructive sleep apnea: BMI of 30 or higher plus an apnea-hypopnea index (AHI) of 15 or higher.
MASH (metabolic dysfunction-associated steatohepatitis): fibrosis stage F2-F3.

Weight loss on its own is excluded under every pathway. If your only goal is weight loss and you do not have one of these qualifying diagnoses, Iowa Medicaid will not cover the medication.

Did Iowa Medicaid stop covering GLP-1s? (the myth)

A widely repeated claim is that “Iowa Medicaid stopped covering GLP-1s in 2026.” That is false, and it is worth clearing up. Iowa never covered GLP-1s for weight loss in the first place, so there was nothing to “stop.” Iowa also was not part of the 2025 wave of states that dropped weight-loss GLP-1 coverage — that group, which included states such as California and Pennsylvania, did not include Iowa.

Two related myths are also worth correcting:

“Wegovy and Zepbound aren’t on the Iowa PDL.” They are — both are listed as Preferred. The catch is that only their non-weight-loss indications are covered.
“Ozempic is non-preferred in Iowa.” It is actually a preferred diabetes agent.

The accurate picture is simple: Iowa covers GLP-1s for diabetes and for specific non-obesity diagnoses, and has consistently excluded weight loss alone.

What if Iowa Medicaid denies your GLP-1?

A denial is not the end of the road. You have formal appeal rights, and there is one move that helps far more often than a generic appeal.

Internal MCO appeal: file within 60 days of the denial. Standard appeals are decided in roughly 30 days; expedited appeals (when delay could seriously harm your health) in about 72 hours.
State Fair Hearing: if the MCO appeal fails, you can request a State Fair Hearing within 120 days through Iowa HHS Appeals at 888-723-9637.
Re-route to a covered diagnosis: the highest-yield step is to work with your prescriber to align the request with a genuinely covered indication — type 2 diabetes, cardiovascular-risk reduction, OSA, or MASH — when that is clinically valid for you. A request for weight loss alone will keep being denied no matter how many times you appeal.

GLP-1 alternatives for Iowa Medicaid members

If you do not qualify for a covered indication, you still have options outside of Medicaid. Cash-pay telehealth programs offer compounded semaglutide or tirzepatide for roughly $200-$400 per month. Be aware that compounded versions are not FDA-approved and are not Medicaid-covered. Manufacturer copay cards generally exclude Medicaid members, so they are usually not an option here.

Ro Body Program

A telehealth weight-management program with clinician oversight and access to branded and compounded GLP-1 options, billed as a monthly membership.

Remedy Meds

A cash-pay telehealth service offering compounded semaglutide and tirzepatide with transparent monthly pricing and home delivery.

See Remedy Meds pricing

Want to weigh the full field side by side? Compare GLP-1 telehealth programs.

How to apply for prior authorization

If your prescription qualifies for a covered indication, here is how the PA process typically works:

1. Confirm the diagnosis. Make sure your chart documents a covered indication — type 2 diabetes for the diabetes pathway, or CV-risk, OSA, or MASH for Wegovy/Zepbound.
2. Choose the right form. Use form 470-5259 for the diabetes GLP-1 pathway, or form 470-0058 for the non-diabetes indications.
3. Gather supporting data. For diabetes, include a current A1C value; for CV-risk, OSA, or MASH, include the relevant BMI, AHI, or fibrosis-stage documentation.
4. Have your prescriber submit the PA. Your clinician sends the completed form to your MCO (Iowa Total Care, Wellpoint Iowa, or Molina Iowa).
5. Track the decision and appeal if needed. If denied, file an internal appeal within 60 days, and consider re-routing to a covered diagnosis if appropriate.

Frequently asked questions

Does Iowa Medicaid cover Wegovy for weight loss?

No. Wegovy is listed as Preferred on the Iowa PDL, but the listing carries a note that the weight-loss indication is not covered. Iowa Medicaid only covers Wegovy for cardiovascular-risk reduction (BMI 27 or higher plus established cardiovascular disease, age 18+), not for weight loss alone.

Did Iowa Medicaid stop covering GLP-1s?

No. Iowa never covered GLP-1s for weight loss, so there was nothing to discontinue, and Iowa was not part of the 2025 wave of states (such as California and Pennsylvania) that dropped weight-loss GLP-1 coverage. Iowa continues to cover GLP-1s for diabetes and for specific non-obesity diagnoses.

Does Iowa Medicaid cover Ozempic?

Yes, for type 2 diabetes with prior authorization. Ozempic is a preferred diabetes agent on the statewide Iowa PDL, despite a common misconception that it is non-preferred. It is not covered for weight loss.

Does Iowa Total Care cover Mounjaro?

Yes, for type 2 diabetes with prior authorization. Because Iowa uses one statewide PDL, Iowa Total Care follows the same list and criteria as Wellpoint Iowa and Molina Iowa, and Mounjaro is preferred for diabetes across all of them. It is not covered for weight loss.

Does Iowa Medicaid cover Zepbound?

Only for obstructive sleep apnea, not for weight loss. Coverage requires a BMI of 30 or higher plus an apnea-hypopnea index (AHI) of 15 or higher, with prior authorization. The weight-loss indication is explicitly excluded.

How do I appeal an Iowa Medicaid GLP-1 denial?

File an internal appeal with your MCO within 60 days of the denial (standard decisions take about 30 days; expedited about 72 hours). If that fails, request a State Fair Hearing within 120 days through Iowa HHS Appeals at 888-723-9637. The most effective step is often to work with your prescriber to re-route the request to a genuinely covered diagnosis when clinically valid.